The following table presents approximate active half-life data for selected research compounds. Information is provided for educational and laboratory reference only and is not intended for medical or dosing guidance.
| Compound / Material | Approx. Active Half-Life |
|---|---|
| Oral Compounds | |
| Anadrol / Anapolan50 (Oxymetholone) | 8–9 hours |
| Anavar (Oxandrolone) | 9 hours |
| Dianabol (Methandrostenolone) | 4.5–6 hours |
| Methyltestosterone | 4 days |
| Winstrol (Stanozolol, oral) | 9 hours |
| Depot / Injectable Compounds | |
| Deca-Durabolin (Nandrolone Decanoate) | 15 days |
| Equipoise (Boldenone Undecylenate) | 14 days |
| Finaject (Trenbolone Acetate) | 3 days |
| Primobolan (Methenolone Enanthate) | 10.5 days |
| Sustanon / Omnadren | 15–18 days |
| Testosterone Cypionate | 12 days |
| Testosterone Enanthate | 10.5 days |
| Testosterone Propionate | 4.5 days |
| Testosterone Suspension | 1 day |
| Winstrol (Stanozolol, injectable) | 1 day |
| Common Ester References | |
| Formate | 1.5 days |
| Acetate | 3 days |
| Propionate | 4.5 days |
| Phenylpropionate | 4.5 days |
| Butyrate | 6 days |
| Valerate | 7.5 days |
| Hexanoate | 9 days |
| Caproate / Isocaproate | 9 days |
| Heptanoate | 9 days |
| Enanthate | 10.5 days |
| Octanoate | 10.5 days |
| Cypionate | 12 days |
| Nonanoate | 12 days |
| Decanoate | 13.5 days |
| Undecanoate | 15–16.5 days |
| Ancillary & Reference Compounds | |
| Arimidex | 3 days |
| Clenbuterol | 1.5 days |
| Clomid | 5 days |
| Cytadren | 6 hours |
| Ephedrine | 6 hours |
| T3 (Triiodothyronine) | 10 hours |
All data are provided for laboratory reference and educational use only. Values are approximate and may vary depending on formulation and analytical conditions.
PCT (Post-Cycle Therapy) is commonly discussed in the context of restoring hormonal balance after exogenous androgen exposure. During a “cycle,” endogenous testosterone output can down-regulate while aromatase activity may increase, influencing the balance between androgens and estrogens. When exogenous inputs are withdrawn, relative estrogen activity can remain elevated versus declining androgens. The overview below summarizes research and educational concepts used to describe strategies for managing these dynamics.
